Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Treasury Shares (2023 - 2025)

Monte Rosa Therapeutics' Treasury Shares history spans 3 years, with the latest figure at $775765.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 591.67% year-over-year to $775765.0; the TTM value through Dec 2025 reached $775765.0, up 591.67%, while the annual FY2025 figure was $775765.0, 591.67% up from the prior year.
  • Treasury Shares reached $775765.0 in Q4 2025 per GLUE's latest filing, roughly flat from $774675.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $894334.0 in Q1 2025 to a low of $14696.0 in Q4 2023.
  • Average Treasury Shares over 3 years is $373866.3, with a median of $243392.0 recorded in 2023.
  • The largest YoY upside for Treasury Shares was 663.19% in 2024 against a maximum downside of 55.18% in 2024.
  • A 3-year view of Treasury Shares shows it stood at $14696.0 in 2023, then soared by 663.19% to $112159.0 in 2024, then soared by 591.67% to $775765.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Treasury Shares are $775765.0 (Q4 2025), $774675.0 (Q3 2025), and $777325.0 (Q2 2025).